Precision BioSciences initiated with a Buy at Jefferies. Jefferies analyst Maury Raycroft started Precision BioSciences with a Buy rating and $25 price target. The analyst believes the company’s proprietary gene-editing technology and platform should provide long-term value.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.